Disruption of autophagy by increased 5-HT alters gut microbiota and enhances susceptibility to experimental colitis and Crohn's disease

• Published in: Science advances Vol. 7; no. 45; p. eabi6442
• Main Authors: Haq, Sabah, Wang, Huaqing, Grondin, Jensine, Banskota, Suhrid, Marshall, John K, Khan, Irfan I, Chauhan, Usha, Cote, Francine, Kwon, Yun Han, Philpott, Dana, Brumell, John H, Surette, Michael, Steinberg, Gregory R, Khan, Waliul I
• Format: Journal Article
• Language: English
• Published: United States American Association for the Advancement of Science (AAAS) 05.11.2021; American Association for the Advancement of Science
• Subjects: Biomedicine and Life Sciences; Diseases and Disorders; Life Sciences; Microbiology; SciAdv r-articles
• ISSN: 2375-2548; 2375-2548
• DOI: 10.1126/sciadv.abi6442

Autophagy, an essential intracellular recycling process, is linked to the pathogenesis of various diseases including Crohn’s disease (CD). Factors that lead to the development of impaired autophagy during intestinal inflammation remain largely unexplored. Here, we report the impact of the interaction between serotonin [5-hydroxytryptamine;(5-HT)] and autophagy in colitis in mouse and human studies. In mice, increased gut 5-HT inhibited autophagy and led to enhanced colitis susceptibility. Reciprocally, mice with reduced 5-HT exhibited up-regulated autophagy via the mammalian target of rapamycin pathway, which resulted in significantly decreased colitis. Deletion of autophagy gene, Atg7, in an epithelial-specific manner, in concert with reduced 5-HT, promoted the development of a colitogenic microbiota and abolished the protective effects conferred by reduced 5-HT. Notably, in control and patient peripheral blood mononuclear cells, we uncovered that 5-HT treatment inhibited autophagy. Our findings suggest 5-HT as a previously unidentified therapeutic target in intestinal inflammatory disorders such as CD that exhibits dysregulated autophagy.